Fundplus is a long-term equity investment firm that focuses on life sciences companies.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Fundplus is a long-term equity investment firm that focuses on life sciences companies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2012 | ITeos Therapeutics | Series A | 11.8M |
2/2022 | TargED Biopharmaceuticals | Series A | 0 |
12/2021 | EyeD Pharma | Venture Round | 0 |
9/2017 | Immunic Therapeutics | Series A | 11.9M |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
11/2022 | Novadip Biosciences | Series B | 23.4M |
10/2021 | Novadip Biosciences | Series B | 0 |
4/2020 | ITeos Therapeutics | Series B | 0 |
11/2017 | Coave Therapeutics | Series B | 22M |
10/2021 | Egle Therapeutics | Series A | 0 |
10/2016 | Promethera Biosciences | Series C | 10.9M |
6/2018 | ITeos Therapeutics | Series B | 0 |
12/2017 | Aelin Therapeutics | Series A | 31.8M |
7/2020 | ExeVir Bio | Series A | 0 |
5/2022 | Tubulis | Series B | 0 |
9/2018 | Minoryx Therapeutics | Series B | 0 |
5/2019 | Confo Therapeutics | Series A | 33.6M |
6/2020 | Ona Therapeutics | Series A | 33.8M |
5/2022 | Minoryx Therapeutics | Series C | 0 |
8/2022 | AstriVax | Seed Round | 30M |
8/2021 | Cardior Pharmaceuticals | Series B | 0 |
5/2019 | EyeD Pharma | Funding Round | 31.3M |
6/2020 | eTheRNA immunotherapies | Series B | 0 |
7/2020 | Indigo Diabetes | Series B | 0 |
1/2017 | OCTIMET Oncology | Series A | 12M |
5/2022 | Minoryx Therapeutics | Series C | 0 |
5/2022 | Tubulis | Series B | 0 |
2/2022 | TargED Biopharmaceuticals | Series A | 0 |
12/2021 | EyeD Pharma | Venture Round | 0 |
10/2021 | Novadip Biosciences | Series B | 0 |
10/2021 | Egle Therapeutics | Series A | 0 |
8/2021 | Cardior Pharmaceuticals | Series B | 0 |
7/2020 | ExeVir Bio | Series A | 0 |
7/2020 | Indigo Diabetes | Series B | 0 |
6/2020 | Ona Therapeutics | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|